Description of Seelos Therapeutics Inc's Business Segments

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and other indications with significant unmet medical needs. The company centers its research and clinical development efforts on a range of psychotropic and neurodegenerative conditions.

Segments
Seelos operates mainly within the following segments, which reflect its areas of research and development focus:

1. Neuropsychiatric Disorders: This segment involves the development of therapies aimed at treating disorders such as depression, anxiety, and post-traumatic stress disorder (PTSD). The company looks to address the limitations of existing treatments, particularly for those patients who do not respond adequately to traditional therapies.

2. Neurodegenerative Disorders: Seelos is engaged in research targeting neurodegenerative conditions like Alzheimer’s disease and Parkinson’s disease. The goal in this segment is to develop therapies that can slow the progression of these diseases and improve the quality of life for affected individuals.

3. Orphan Diseases: The company also focuses on developing treatments for rare diseases that often lack effective therapies. This includes specific genetic or metabolic disorders where there is a high need for innovation.

Products and Services

Product Candidates

1. SLS-002: This is a ketamine nasal spray being developed for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder (MDD). The formulation aims to provide rapid relief from depressive symptoms and an overall enhancement of mood.

2. SLS-005: This product is a formulation of the investigational drug, known as Trehalose, which is being developed for the treatment of neurologically-based disorders. Trehalose is considered for conditions such as Amyotrophic Lateral Sclerosis (ALS) and potentially for other neurodegenerative diseases due to its cellular protective properties.

3. SLS-006: This candidate is being explored for its efficacy in treating Parkinson’s disease by targeting the underlying biological mechanisms of neurodegeneration. It aims to mitigate symptoms and slow the disease progression.

4. SLS-007: This novel therapy addresses post-traumatic stress disorder (PTSD) and aims to provide improved outcomes for individuals suffering from chronic stress and trauma-related issues.

5. SLS-008: Targeted towards patients with multiple sclerosis, this product candidate seeks to alleviate symptoms and improve functional outcomes through innovative neuroprotective strategies.

Research Services

Seelos Therapeutics also provides research services focusing on CNS drug development. This includes:

- Clinical Trial Management: Overseeing and managing clinical trials for their products and collaborations with other research institutions.
- Regulatory Expertise: Assistance with navigating the regulatory landscape for drug development, including FDA submissions and compliance.
- Biomarker Development: Developing and validating biomarkers for better patient stratification and efficacy measurement during clinical trials.

Seelos Therapeutics aims to leverage partnerships with research institutions and pharmaceutical companies to advance its product pipeline while ensuring the safety and therapeutic efficacy of its candidates. This positions them strategically in a competitive biopharmaceutical landscape, focusing on delivering novel therapies that meet urgent medical needs.

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.